Jardiance Manufacturer Bridge Programs: How to Get Empagliflozin Cheaper in 2026

What Is a Manufacturer Bridge Program and Why Does It Exist?

A bridge program gives patients a short supply of medication at no cost or sharply reduced cost during a defined waiting period. The wait is usually a prior authorization review, a formulary exception appeal, a Medicare open-enrollment window, or the first billing cycle after a new prescription is written.

For Jardiance specifically, the bridge matters because the drug's list price sits near $700 for 30 tablets, and SGLT2 inhibitors frequently require step-therapy documentation before commercial insurers will approve them. EMPA-REG OUTCOME established the cardiovascular mortality benefit that now underpins most prescribing guidelines, yet payer prior authorization queues can still run two to four weeks. [1]

Why SGLT2 Inhibitors Get Stuck in Prior Auth

The 2023 American Diabetes Association Standards of Care explicitly recommend SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, heart failure, or diabetic kidney disease, regardless of A1C. [2] Despite that guideline language, many commercial plans still require documented failure of metformin before approving empagliflozin. That documentation step creates the gap a bridge program is designed to fill.

Who Administers the Jardiance Bridge?

Boehringer Ingelheim and Eli Lilly split commercial responsibilities. BI manages the clinical pipeline; Lilly handles a large share of the patient-services infrastructure through Lilly Cares. Prescribers may route bridge requests through either partner's hub, and both feed into the same underlying medication supply.

The Jardiance Savings Card (Co-Pay Assistance)

The savings card is the most widely used access tool. Eligible patients with commercial insurance pay a fixed monthly amount, often $10, sometimes $25 depending on current program terms, and the card covers the remainder up to a defined annual cap.

The FDA's framework for prescription drug affordability does not regulate manufacturer co-pay programs directly, but 340B and anti-kickback guidance shapes how these cards interact with federal insurance. [3] That interaction is the single biggest eligibility restriction.

Eligibility Requirements

To use the savings card in 2026, a patient generally must:

• Have commercial (private) insurance that covers Jardiance
• Be a U.S. Resident
• Not be enrolled in any federal- or state-funded program including Medicare Part D, Medicaid, TRICARE, or the VA
• Have a valid prescription for an FDA-approved indication

Patients who are commercially insured but whose plan places Jardiance on a non-preferred tier paying 40 to 50% coinsurance get the most financial relief from this card. A patient paying $320 out-of-pocket per fill could drop that to $10 overnight.

Annual Cap and Reset

Savings card programs reset on January 1 each year. The annual maximum benefit has historically been around $3,600 to $5,200 depending on the plan year, but BI and Lilly update terms without advance notice. Always verify the current cap at the time of enrollment through the official Jardiance savings program portal or by calling 1-800-545-6962.

How to Enroll

Enrollment takes three to five minutes online or at the pharmacy counter. The prescriber does not need to do anything. Patients provide their insurance card information, generate a savings card number, and present it alongside their insurance card at the pharmacy. Some pharmacies can process the discount in a single transaction; others require a two-step adjudication.

Patient Assistance Programs for Uninsured and Underinsured Patients

Patients without insurance, or with insurance that does not cover Jardiance at all, have two primary pathways: the BI patient assistance program and the Lilly Cares Foundation program. Both can provide medication at no cost.

The NIH's National Institute of Diabetes and Digestive and Kidney Diseases notes that approximately 11.3% of the U.S. Population has diabetes, with a disproportionate burden among lower-income populations who are least likely to maintain consistent insurance. [4] Patient assistance programs exist precisely to reach this group.

Boehringer Ingelheim Cares Foundation

The BI Cares Foundation accepts applications from patients who meet income criteria, currently set at or below 400% of the federal poverty level for most programs. A household of two at 400% FPL in 2026 earns roughly $80,000 annually. The application requires:

• Proof of income (most recent federal tax return or three recent pay stubs)
• Proof of residency
• A completed and signed prescriber attestation
• Documentation that the patient lacks adequate prescription coverage for Jardiance

Processing takes approximately two to four weeks. Approved patients receive a 90-day supply by mail with automatic renewals every 90 days as long as they re-certify income annually.

Lilly Cares Foundation

Lilly Cares runs a parallel program with similar income thresholds. Because BI and Lilly co-promote Jardiance, patients may apply through either foundation; the drug supplied is identical. Lilly Cares historically has maintained slightly faster processing turnaround, often 10 to 14 business days, for patients who submit complete documentation on the first attempt.

The Lilly Cares program is anchored in Lilly's broader access commitments, which the company has disclosed in FDA-filed documents related to its patient support infrastructure. [5]

What Happens During the Waiting Period

This is where the bridge function activates. A prescriber can request a bridge supply of 30 days of Jardiance at no charge to the patient while the full patient assistance application processes. The bridge is not automatic; the prescriber or their staff must request it explicitly when submitting the assistance application. Most hub coordinators can authorize a bridge within 48 to 72 hours of a complete application submission.

Medicare and Jardiance: Why Co-Pay Cards Do Not Work

Medicare Part D beneficiaries cannot use manufacturer co-pay cards. Federal anti-kickback statute interpretations, confirmed in a 2022 HHS Office of Inspector General advisory opinion, prohibit this arrangement because it could influence drug selection in a federally funded benefit. [6]

The table below maps the four realistic cost-reduction paths for Medicare patients.

| Program | Monthly Out-of-Pocket | Income Limit | Notes | |---|---|---|---| | Extra Help (LIS) | $4, $10 | <150% FPL | Apply through SSA | | Medicare Savings Program | Varies | <135 to 150% FPL | State-administered | | BI/Lilly PAP | $0 | <400% FPL | Requires no Part D coverage for Jardiance | | GoodRx / NeedyMeds | $180, $260 | None | Cannot combine with Part D at same pharmacy |

Extra Help (Low Income Subsidy)

Extra Help is a federal subsidy that reduces Part D cost-sharing for qualifying Medicare beneficiaries. In 2026, full Extra Help beneficiaries pay no more than $10.35 for brand drugs in the coverage gap. Patients apply through the Social Security Administration at ssa.gov or through their State Health Insurance Assistance Program (SHIP). A 2021 JAMA Internal Medicine analysis found that only 74% of eligible individuals actually enrolled in Extra Help, leaving roughly 2 million people paying full Part D cost-sharing unnecessarily. [7]

Medicare Inflation Reduction Act Changes

The Inflation Reduction Act caps out-of-pocket spending under Medicare Part D at $2,000 per year starting in 2025. For patients whose only high-cost drug is Jardiance, this cap may reduce annual exposure significantly compared with prior years when the catastrophic phase had no ceiling. [8]

How to Get Jardiance Cheaper: Six Practical Strategies

Getting the price down on empagliflozin does not require a single program. Stacking legal, compatible strategies produces the largest reduction.

Strategy 1: Confirm the Correct FDA Indication on the Prescription

Jardiance carries three FDA-approved indications as of 2026: type 2 diabetes (approved 2014), heart failure with reduced ejection fraction (approved 2021, confirmed in EMPEROR-Reduced with N=3,730), and chronic kidney disease (approved 2023 following EMPA-KIDNEY). [9, 10] Some insurance plans cover the heart failure or CKD indication on a more favorable tier than the diabetes indication. A prescriber who writes the diagnosis code for CKD stage 3b with proteinuria rather than type 2 diabetes alone may trigger a lower patient copay without any formulary exception.

Strategy 2: Request a 90-Day Supply

Most pharmacy benefit managers apply a lower dispensing fee to 90-day fills, and the co-pay card's per-transaction fee is charged once per fill rather than once per 30 days. A patient paying $10 per fill saves $20 per year by switching to quarterly fills. Patients who are close to the annual cap benefit more by stretching fills across fewer transactions.

Strategy 3: Appeal Step-Therapy Requirements

Step-therapy protocols that require metformin failure before approving an SGLT2 inhibitor may be medically inappropriate for patients with established cardiovascular disease or CKD. The 2022 ADA/EASD consensus report on type 2 diabetes management explicitly states that in patients with atherosclerotic cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor should be started independent of background glucose-lowering therapy. [11] A prescriber letter citing this guideline, paired with the patient's documented diagnosis, succeeds in overturning step-therapy requirements in a substantial share of commercial appeals.

Strategy 4: Use GoodRx Only When Not Using Insurance

GoodRx discounts cannot be combined with insurance at most pharmacies and cannot be combined with the manufacturer savings card. GoodRx produces prices of approximately $185 to $260 for 30 tablets of empagliflozin 10 mg at major chains in 2026. This is useful only for patients who are uninsured and waiting for patient assistance program approval, or for Medicare patients in the pre-Extra Help enrollment window.

Strategy 5: Ask About Samples

Prescribers who are enrolled BI or Lilly representatives may have sample packs. A typical office sample is a 7-to-14-day supply. While samples do not solve long-term cost, they cover the first two weeks of therapy while savings card enrollment or PAP applications process.

Strategy 6: Check State Pharmaceutical Assistance Programs

Twenty-three states operate pharmaceutical assistance programs for residents who do not qualify for Medicaid but cannot afford brand medications. Eligibility criteria and covered drugs vary by state. The National Conference of State Legislatures maintains a current list updated annually. Several state programs will cover Jardiance specifically when the prescriber documents cardiovascular or renal indication.

HSA and FSA Eligibility for Jardiance

Yes, Jardiance is an eligible expense under a Health Savings Account or Flexible Spending Account. The IRS defines eligible medical expenses in Publication 502, which includes prescription drugs obtained with a valid prescription. [12] Empagliflozin qualifies without a letter of medical necessity because it is not a dual-use item (it has no OTC equivalent and no cosmetic application).

How to Pay and Document

Patients can pay for Jardiance directly with their HSA debit card at the pharmacy. Alternatively, they can pay out-of-pocket and submit a reimbursement claim to their HSA administrator with the pharmacy receipt. The receipt must show:

• The drug name (empagliflozin or Jardiance)
• The dispensing date
• The amount paid
• The pharmacy name

FSA accounts follow the same rules but are subject to the use-it-or-lose-it rule unless the employer offers a grace period or $640 rollover. Patients expecting a large Jardiance expense in a plan year should allocate FSA funds accordingly at open enrollment.

Combining HSA/FSA with the Savings Card

A patient can use the savings card to reduce the cost charged to the pharmacy, then pay the remaining $10 co-pay with an HSA card. This is the optimal approach for commercially insured patients: the manufacturer subsidizes the bulk of the cost, and the patient's pre-tax HSA dollars cover the rest. The IRS has not issued specific guidance restricting this combination, and it is widely used in practice. [12]

Empagliflozin's Clinical Case: Why Paying for This Drug Matters

Cost-assistance programs gain urgency when the clinical stakes are high. EMPA-REG OUTCOME (N=7,020) showed a 38% relative risk reduction in cardiovascular death (3.7% vs. 5.9%, hazard ratio 0.62, P<0.001) in patients with type 2 diabetes and established cardiovascular disease treated with empagliflozin 10 mg or 25 mg versus placebo over a median 3.1 years. [1]

The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% compared with placebo (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF regardless of diabetes status. [9]

In EMPA-KIDNEY (N=6,609), empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) in patients with CKD. [10] The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines now give SGLT2 inhibitors a Grade 1A recommendation for CKD patients with eGFR 20 to 45 mL/min/1.73m2. [13]

These outcomes mean that a patient who cannot afford Jardiance and discontinues it faces a measurable increase in the probability of a hospitalization or death from a preventable cause. Access programs are not an administrative convenience. They are part of the clinical plan.

The American Diabetes Association's 2023 Standards of Care state directly: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events." [2]

What Prescribers Need to Do

Getting a patient into a bridge or assistance program requires prescriber action, not just patient action. The steps are:

1. Identify the access barrier at the time of prescribing (no insurance, high copay, pending PA).
2. Contact the BI/Lilly hub at 1-800-545-6962 or use the electronic prior authorization tool in the prescriber's EHR.
3. Request a bridge supply explicitly if the PA review will take more than five business days.
4. Provide a signed letter of medical necessity for PAP applications citing the relevant FDA indication and guideline language.
5. Document the access program enrollment in the patient chart so the care team can monitor adherence and renewal.

A 2020 BMJ analysis of medication adherence in SGLT2 inhibitor users found that out-of-pocket cost was the strongest modifiable predictor of 90-day non-persistence, with patients facing cost-sharing above $50 per month having 1.8 times the odds of discontinuation compared with patients paying under $10. [14]

The FDA's drug safety communication on empagliflozin confirms active post-market surveillance for this drug class, underscoring the regulatory infrastructure supporting its long-term use. [15]